|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Maia Building (B270), Babraham Research Campus, Cambridge, GB
|
|
Xap Therapeutics, formerly known as Rockend Ltd., is a start-up biotechnology company which is developing an innovative, synthetic biology driven platform for cell therapeutics. Based in Cambridge, UK, the company was founded by a group of experienced biotech entrepreneurs with significant funding from well-known US/UK blue-chip VCs. Xap Therapeutics applies CRISPR technology to engineer iPSCs. These iPSCs form the basis of a universal cell platform producing a “chassis” cell, which we can further functionalise into cell therapies by expression of genetically engineered constructs. Our cell products will have the ability to process external cues via engineered receptors and to release various types of cargos upon activation. The ultimate aim is to create novel cell therapies with mechanisms of action that are beyond reach of current approaches, thus bringing a step change improvement in the treatment of serious disease, including autoimmunity and cancer.
We are hiring across a range of R&D functions and are looking to build an exceptional team out of industry and academia. This is a unique career opportunity for talented people to join our growing team, and to contribute to the generation of this exciting synthetic cell therapy platform and future clinical products. You will enjoy a varied and rewarding role and a flexible and dynamic working environment which values innovation and teamwork.
|
Xap Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Xap Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Xap Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.